A case of INR elevation with remdesivir and warfarin in a hospitalized patient with COVID-19

Liyan Yao; William Byas; Matthew Li; Merjona Saliaj

doi:10.5430/crim.v8n1p9

Case Reports in Internal Medicine ›› 2021, Vol. 8 ›› Issue (1) :9 -12. DOI: 10.5430/crim.v8n1p9

CASE REPORTS

research-article

A case of INR elevation with remdesivir and warfarin in a hospitalized patient with COVID-19

Author information +

History +

PDF (282KB)

Abstract

Treatments for COVID-19 infection have varied widely within the past year. Remdesivir is the only direct-acting antiviral approved by the Food and Drug Administration with demonstrated efficacy in the management of patients with COVID-19.[1] Commonly reported adverse effects include hepatotoxicity and gastrointestinal symptoms such as nausea and diarrhea. Less common adverse effects include respiratory toxicity, cardiovascular toxicity and nephrotoxicity.[2] We report a case of international normalized ratio (INR) prolongation in a COVID-19 patient receiving concomitant warfarin and remdesivir therapy.

Keywords

Remdesivir / Warfarin / SARS-CoV-2 / COVID-19 / Hematology

Cite this article

Download citation ▾

Liyan Yao, William Byas, Matthew Li, Merjona Saliaj. A case of INR elevation with remdesivir and warfarin in a hospitalized patient with COVID-19. Case Reports in Internal Medicine, 2021, 8(1): 9-12 DOI:10.5430/crim.v8n1p9

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016; 531(7594): 381-385. PMid:26934220. https://doi.org/10.1038/nature17180

[2]	Ali MJ, Hanif M, Haider MA, et al. Treatment Options for COVID- 19: A Review. Frontiers in Medicine. 2020; 7: 480. PMid:32850922. https://doi.org/10.3389/fmed.2020.00480

[3]

de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proceedings of the National Academy of Sciences of the United States of America. 2020; 117(12): 6771-6776. PMid:32054787. https://doi.org/10.1073/pnas.1922083117

[4]	Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. The New England Journal of Medicine. 2021; 384(6): 497-511. PMid:33264556. https://doi.org/10.1056/NEJMoa2023184

[5]	Zampino R, Mele F, Florio LL, et al. Liver injury in remdesivirtreated COVID-19 patients. Hepatology International. 2020; 14(5): 881-883. PMid:32725454. https://doi.org/10.1007/s12072-020-10077-3

[6]	Olry A, Meunier L, Délire B, et al. Drug-Induced Liver Injury and COVID-19 Infection: The Rules Remain the Same. Drug safety. 2020; 43(7): 615-617. PMid:32514859. https://doi.org/10.1007/s40264-020-00954-z

[7]	Manigaba K, Hawks J, Kima M. Remdesivir-Warfarin Interaction: A Case Report. HCA Healthcare Journal of Medicine. 2020; 1: 0. https://doi.org/10.36518/2689-0216.1164

[8]

Leegwater E, Strik A, Wilms EB, et al. Drug-induced Liver Injury in a Patient With Coronavirus Disease 2019: Potential Interaction of Remdesivir With P-Glycoprotein Inhibitors. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2021; 72(7): 1256-1258. PMid:32594120. https://doi.org/10.1093/cid/ciaa883

[9]	Saum LM, Balmat RP. Ceftriaxone Potentiates Warfarin Activity Greater Than Other Antibiotics in the Treatment of Urinary Tract Infections. Journal of Pharmacy Practice. 2021; 29(2): 121-124. PMid:25092605. https://doi.org/10.1177/0897190014544798

[10]	Holbrook AM, Pereira JA, Labiris R, et al. Systematic Overview of Warfarin and Its Drug and Food Interactions. Arch Intern Med. 2005; 165(10): 1095-1106. PMid:15911722. https://doi.org/10.1001/archinte.165.10.1095

[11]	Hazlewood KA, Fugate SE, Harrison DL. Effect of oral corticosteroids on chronic warfarin therapy. The Annals of Pharmacotherapy. 2006; 40(12): 2101-2106. PMid:17119104. https://doi.org/10.1345/aph.1H418